Mechelen, Belgium; 13 January 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 30,000 subscription rights under a new employee subscription right plan.

Read more:
Galapagos creates new subscription right plan

-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed-

View original post here:
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading...

MOUNTAIN VIEW, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Veranome Biosystems LLC announced today that it has entered a collaboration and licensing agreement with Cold Spring Harbor Laboratory (CSHL) that adds in-situ sequencing technology to Veranome’s spatial omics portfolio. Veranome now has one of the most comprehensive portfolios of assay technologies that can allow targeted mapping of cellular spatial gene expressions with multiplexed in-situ hybridization (ISH) as well as de-novo profiling of cellular transcripts using in-situ sequencing. The expanded assay portfolio coupled with Veranome’s advanced imaging capabilities will enable customers to explore a broad range of applications, including characterization of cell and gene therapies methods and CRISPR screens. Veranome will further develop these high-sensitivity assay chemistries to offer researchers the ability to profile archival FFPE tissue blocks with the same spatial resolution as fresh frozen samples when analyzed on Veranome’s Spatial Analyzer.

Read more from the original source:
Veranome Biosystems and Cold Spring Harbor Laboratory Enter Collaboration and Licensing Agreement to Develop Advanced In-Situ Sequencing Technologies

BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

See original here:
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

Live webcast will be at 8:30 a.m. EST on January 25 Live webcast will be at 8:30 a.m. EST on January 25

Read the original post:
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics...

Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

View post:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile

More here:
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

California-based cannabis leader adds veteran finance executive and investor to leadership team California-based cannabis leader adds veteran finance executive and investor to leadership team

Read more:
Lowell Farms Welcomes Jeff Monat to Board of Directors

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii.

Read more:
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will participate at Redeye Fight Cancer Seminar on January 20, 2022.

Read the original:
LIDDS presents at Redeye Fight Cancer Seminar

— Meeting to Reconvene on January 18, 2022 —

Continue reading here:
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

RADNOR, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, responded to today’s press release issued by Relief Therapeutics.

More here:
NRx Responds to Relief’s Allegations of January 14, 2022

Bagsværd, Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs.

Go here to read the rest:
Novo Nordisk announces settlement of securities lawsuit in Denmark

John Dawson to retire from Oxford Biomedica

Go here to read the rest:
John Dawson to retire from Oxford Biomedica

NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer. Dominique Costantini, current Chairwoman of OSE Immunotherapeutics’ Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim Chief Executive Officer, effective immediately. A search for a new CEO has been launched with the assistance of a leading executive search firm.

View original post here:
OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.

Go here to see the original:
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

See the original post here:
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

IRB approval to initiate Phase 2 study for methamphetamine abuse disorders

Read more:
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022 Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022

The rest is here:
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Read the original post:
Sanofi: Information concerning the total number of voting rights and shares – December 2021